# A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke

Study · id `cardio:ct-nct07842185` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07842185](<https://clinicaltrials.gov/study/NCT07842185>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07842185

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1192 participants.

## Technical summary

Registry record NCT07842185. Randomized; double masking; primary purpose treatment. Start 2026-12-19 (anticipated); primary completion 2030-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 1192 participants (planned count; ClinicalTrials.gov record NCT07842185, source copy `cardio:ctgov-nct07842185-2026-11-06`, retrieved 2026-11-18)
- Planned start: 2026-12-19 (anticipated) (ClinicalTrials.gov record NCT07842185, source copy `cardio:ctgov-nct07842185-2026-11-06`, retrieved 2026-11-18)
- Primary completion: 2030-12-30 (anticipated) (ClinicalTrials.gov record NCT07842185, source copy `cardio:ctgov-nct07842185-2026-11-06`, retrieved 2026-11-18)
- Completion: 2031-05-08 (anticipated) (ClinicalTrials.gov record NCT07842185, source copy `cardio:ctgov-nct07842185-2026-11-06`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT07842185, source copy `cardio:ctgov-nct07842185-2026-11-06`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07842185-2026-11-06`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
- Acronym: INSTANT-2
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Tirofiban Injection
- Intervention (Drug): Tirofiban Injection
- Lead sponsor: Xinqiao Hospital of Chongqing
- Lead sponsor class: OTHER
- Collaborator: The Affiliated Ganzhou Hospital of Nanchang University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Xinqiao Hospital of Chongqing (`cardio:org-xinqiao-hospital-of-chongqing`)

## Provenance

Content hash: c593732ccf767351335983ffb001f23b7a9d730362cea9d7a357539196833d1d
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
